ABVX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Abivax SA (ABVX) is not a strong buy at the moment for a beginner investor with a long-term strategy. While the company has promising developments in its drug pipeline and financial stability, the lack of immediate positive trading signals, bearish technical indicators, and mixed analyst ratings suggest caution. The investor may consider waiting for the Q2 trial readout for clearer direction.
The MACD is negatively expanding at -0.865, RSI is neutral at 29.626, and moving averages are converging, indicating no clear bullish momentum. The stock is trading below its pivot level (117.676) and nearing key support levels (S1: 110.506, S2: 106.077), suggesting potential downside risk.
to fund operations into Q4
Analysts from Barclays, Jefferies, Morgan Stanley, and BTIG have raised price targets and remain optimistic about the company's drug pipeline.
The stock has declined due to denied acquisition rumors and faces competition in the pharmaceutical market. Wedbush has issued an Underperform rating, citing substantial downside risk if clinical trials fail. Technical indicators are bearish, and the stock has a low probability of significant short-term gains.
Abivax reported a strong cash position of €530.4 million as of December 2025, ensuring financial stability into Q4 2027. However, research and development expenses increased to €177.8 million in 2025, reflecting heavy investment in drug development.
Analyst ratings are mixed. Barclays, Jefferies, Morgan Stanley, and BTIG are bullish with price targets ranging from $145 to $160, citing strong clinical data and market potential for obefazimod. However, Wedbush has an Underperform rating with a $110 price target, urging caution due to trial risks and speculation around M&A.
